Skip to content
Screener

BioCryst Pharmaceuticals BCRX Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
$3.32M-30.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$19.23M+9.3%
Precigen logo
PrecigenPGEN
$1.07M+15.1%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$2.12M+8.1%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$14.31M+22.4%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$820K+43.9%

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.4B+39.2%
Enterprise value$2.65B+40.4%
P/S2.6×-0.5×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityCurrent.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →

Filed
Aug 5, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053300

FAQ

What is BioCryst Pharmaceuticals's operating lease liabilities (current)?
BioCryst Pharmaceuticals (BCRX) reported operating lease liabilities (current) of $1.91M in Q2 2026.
How has BioCryst Pharmaceuticals's operating lease liabilities (current) changed year-over-year?
BioCryst Pharmaceuticals's operating lease liabilities (current) increased by 387.8% year-over-year, from $392K to $1.91M.
What is the long-term trend for BioCryst Pharmaceuticals's operating lease liabilities (current)?
Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's operating lease liabilities (current) has grown at a -23.1% compound annual growth rate (CAGR), from $1.18M to $317K.
What does operating lease liabilities (current) mean?
The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.

Ask your AI about BioCryst Pharmaceuticals's operating lease liabilities (current).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude